Longeveron (LGVN)
NASDAQ:LGVN
Want to see LGVN full AI Analyst Report?
LGVN Stock Chart & Stats
$1.10
-$0.07(-3.68%)
At close: 4:00 PM EST
$1.10
-$0.07(-3.68%)
Day’s Range― - ―
52-Week Range$0.48 - $1.80
Previous CloseN/A
Volume215.49K
Average Volume (3M)473.11K
Market Cap
$24.04M
Enterprise Value$383.36K
Total Cash (Recent Filing)$15.76M
Total Debt (Recent Filing)$748.00K
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 07, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding30,148,947
10 Day Avg. Volume706,553
30 Day Avg. Volume473,105
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.48
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$5.50Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$1.49M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low debt versus equity reduces near-term solvency risk and gives Longeveron structural financial flexibility. For a cash-burning clinical-stage biotech, low leverage lessens immediate refinancing pressure, preserves strategic options and reduces forced-dilution risk during development milestones.
Strong IP And Expedited DesignationsA broad patent estate and multiple expedited regulatory designations create durable competitive barriers and faster regulatory pathways. These attributes increase attractiveness for partnerships or licensing, support premium pricing potential if approved, and raise the long-term value of the clinical franchise.
Completed Enrollment; Defined Near-term CatalystFinished enrollment and an imminent Aug 2026 topline provide a clear, time-bound clinical catalyst that can materially derisk the program. A near-term result enables focused regulatory engagement and accelerates partnering or licensing decisions that shape the company's strategic path over the next 2–6 months.
Bears Say
Heavy Cash Burn And Limited RunwaySustained negative operating and free cash flow requires near-term external funding. Cash runway into Q4 2026 places financing pressure around a pivotal readout, increasing dilution risk and potentially forcing suboptimal timing for partnerships or asset-light strategies that could dilute long-term shareholder value.
Regulatory Setback And Endpoint UncertaintyThe FDA's rejection of RVEF and the loss of pivotal designation materially raise regulatory risk. Endpoint uncertainty complicates statistical plans and could limit ability to secure approval from this trial, potentially requiring additional studies or prolonged regulatory dialogue that delay commercialization timelines.
Minimal Revenue And Ongoing LossesVery limited commercial revenue and persistent large net losses show the business is not self-sustaining. This structural lack of revenue visibility increases dependence on financing or partnerships to fund development, creating recurring dilution risk and constraining long-term reinvestment capacity.
Longeveron News
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $0.47 and its highest was $1.80 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $24.04M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Aug 07, 2026 which is in 63 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.012.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -0.18.
How many shares outstanding does Longeveron have?
Longeveron has 30,148,947 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -7.02%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
LGVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful operational and strategic progress — completed enrollment for ELPIS II, new institutional investors, a strengthened IP and regulatory-designation profile, and modest improvements in expenses and net loss — alongside material challenges: a regulatory setback where the FDA rejected RVEF as a primary endpoint and no agreement on a new primary endpoint while the trial remains ongoing, objective-only efficacy expectations, limited cash runway into Q4 2026, and small absolute revenues. Management is pursuing partnerships and will seek FDA engagement immediately after topline results, but the regulatory uncertainty and near-term financing timeline temper optimism.View all LGVN earnings summariesLGVN Stock 12 Month Forecast
Average Price Target
$5.50
▲(400.00% Upside)
Technical Analysis
Ibio
―
Edesa Biotech
―
Chemomab Therapeutics
―
Processa Pharmaceuticals
―
FibroBiologics, Inc.
―
Ownership Overview
14.79% Insiders
2.19% Mutual Funds
0.98% Other Institutional Investors
80.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---